These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 807757)

  • 41. [Susceptibility of Pseudomonas aeruginosa recently isolated from clinical specimens to various antimicrobial agents and changes of susceptibility to carbenicillin, gentamicin and amikacin (author's transl)].
    Kosakai N; Oguri T
    Jpn J Antibiot; 1980 Jun; 33(6):668-74. PubMed ID: 6779031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gentamicin-resistant Pseudomonas aeruginosa: Mayo Clinic Experience, 1970-1976.
    Keys TF; Washington JA
    Mayo Clin Proc; 1977 Dec; 52(12):797-801. PubMed ID: 413012
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Gentamicin activity on the phenomenon of transformation of the bacterial flora in hospital conditions].
    Cava L
    G Ital Chemioter; 1969; 16(1):27-33. PubMed ID: 4935434
    [No Abstract]   [Full Text] [Related]  

  • 44. [Common pathogens in burn infection and changes in their drug sensitivity].
    Zhang YP
    Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi; 1991 Jun; 7(2):108-10, 157-8. PubMed ID: 1773380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resistance to gentamicin and amikacin of gram-negative organisms isolated from horses.
    Orsini JA; Benson CE; Spencer PA; Van Miller E
    Am J Vet Res; 1989 Jun; 50(6):923-5. PubMed ID: 2669575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical use of gentamicin in urinary tract infections due to Pseudomonas or Proteus].
    Shiba T; Ohashi N; Kamiya K; Fujieda J; Omuro H
    Hinyokika Kiyo; 1971 Sep; 17(9):601-4. PubMed ID: 5166131
    [No Abstract]   [Full Text] [Related]  

  • 47. [Laboratory and clinical investigation of amikacin (BB-K8) (author's transl)].
    Kato Y; Saito A; Ishikawa K; Nakayama I; Tomizawa M
    Jpn J Antibiot; 1974 Jun; 27(3):343-7. PubMed ID: 4215898
    [No Abstract]   [Full Text] [Related]  

  • 48. [[Fundamental and clinical studies of amikacin (BB-K8) in surgical field (author's transl)]?].
    Shibata K; Fugii M; Shinagawa N; Suzuki Y; Muramatsu
    Jpn J Antibiot; 1974 Oct; 27(5):625-32. PubMed ID: 4218270
    [No Abstract]   [Full Text] [Related]  

  • 49. Antimicrobial susceptibility of gentamicin-resistant Pseudomonas aeruginosa.
    Yu PK; Washington JA
    Mayo Clin Proc; 1977 Dec; 52(12):802-5. PubMed ID: 413013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative study of Amikacin (BB-K8) and gentamicin activity in vitro against Proteus rettgeri.
    Pérez-Rodríguez F; Bermúdez RH; de Brau CJ
    Bol Asoc Med P R; 1977 Jul; 69(7):222-6. PubMed ID: 268183
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical and laboratory investigations on ticarcillin, an anti-pseudomonal antibiotic.
    Wise R; Reeves DS
    Chemotherapy; 1974; 20(1):45-51. PubMed ID: 4210893
    [No Abstract]   [Full Text] [Related]  

  • 52. [Proteus rettgeri strains, resistant to gentamicin with transmissible resistance to kanamycin and carbenicillin (author's transl)].
    Urbàsková P; Torsová V; Dostàl J; Huśłavová V; Krcméry V
    Cesk Epidemiol Mikrobiol Imunol; 1977 May; 26(3):171-4. PubMed ID: 144028
    [No Abstract]   [Full Text] [Related]  

  • 53. [Studies on the in vitro effects of cephalothin and gentamicin, alone and in combination, on proteus mirabilis and enterococci (author's transl)].
    Lode H
    Infection; 1975; 3(2):83-8. PubMed ID: 1102455
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amikacin treatment of Pseudomonas-caused corneal ulcer.
    Hansen KD; Meyer RF
    Arch Ophthalmol; 1980 Nov; 98(11):1991-2. PubMed ID: 6776941
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gentamicin-resistant Pseudomonas aeruginosa corneal ulcers.
    Gelender H; Rettich C
    Cornea; 1984; 3(1):21-6. PubMed ID: 6443074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patterns and mechanisms of emergence of resistance to amikacin.
    Meyer RD
    J Infect Dis; 1977 Sep; 136(3):449-52. PubMed ID: 409785
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections.
    Rodriguez-Noriega E; Esparza-Ahumada S; Morfin-Otero R
    J Chemother; 1995 Jun; 7 Suppl 2():155-60. PubMed ID: 8622105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cefazolin. 3. Double blind controlled trial in urinary tract infections].
    Seika K; Minakawa M; Miyoshi K; Yamaji K; Sugiyama Y
    Jpn J Antibiot; 1972 Apr; 25(2):72-8. PubMed ID: 4627212
    [No Abstract]   [Full Text] [Related]  

  • 59. Amikacin (BB-K8) treatment of multiple-drug resistant Proteus infections.
    Sharp PM; Saenz CA; Martin RR
    Antimicrob Agents Chemother; 1974 May; 5(5):435-8. PubMed ID: 4462458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gentamicin-resistant gram-negative bacilli in hospital patients. Part II. In vitro aspects including susceptibility to tobramycin and amikacin.
    Block CS; Fabian B; Robinson RG
    S Afr Med J; 1978 Mar; 53(11):396-99. PubMed ID: 675374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.